Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Organizing pneumonia in a patient with hodgkin's lymphoma and large B cell lymphoma: a rare association.

Bordas-Martinez J, Gasa M, Domingo-Domènech E, Vicens-Zygmunt V.

Hematol Transfus Cell Ther. 2019 Sep 7. pii: S2531-1379(19)30128-2. doi: 10.1016/j.htct.2019.06.003. [Epub ahead of print] No abstract available.

2.

M7FLIPI AND TARGETED SEQUENCING IN HIGH-RISK FOLLICULAR LYMPHOMA.

Sorigue M, Oliveira A, Mercadal S, Tapia G, Climent F, Perez-Roca L, Lorences I, Domingo-Domenech E, Cabezon M, Navarro JT, Gonzalez-Barca E, Zamora L, Ribera JM, Sureda A, Armengol MP, Sancho JM.

Hematol Oncol. 2019 Sep 2. doi: 10.1002/hon.2674. [Epub ahead of print]

PMID:
31475375
3.

Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance.

Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, Cardozo C, Albasanz-Puig A, Marco F, Laporte-Amargós J, Moreno-García E, Domingo-Doménech E, Chumbita M, Martínez JA, Soriano A, Carratalà J, Garcia-Vidal C.

Clin Infect Dis. 2019 Apr 25. pii: ciz319. doi: 10.1093/cid/ciz319. [Epub ahead of print]

PMID:
31321410
4.

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.

Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, Willenbacher W, Ligon AH, Ouyang J, Redd R, Rodig SJ, Shipp MA, Sacchi M, Sumbul A, Armand P, Ansell SM.

J Clin Oncol. 2019 Aug 10;37(23):1997-2007. doi: 10.1200/JCO.19.00315. Epub 2019 May 21.

PMID:
31112476
5.

Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management.

Sureda A, Domingo-Domenech E, Gautam A.

Crit Rev Oncol Hematol. 2019 Jun;138:1-5. doi: 10.1016/j.critrevonc.2019.03.016. Epub 2019 Mar 29. Review.

6.

Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.

Sorigue M, Bishton M, Domingo-Domenech E, McMillan A, Prusila R, García O, Kuusisto M, Condom M, Tapia G, Ribera JM, Kuittinen O, Fox CP, Sancho JM.

Leuk Lymphoma. 2019 Oct;60(10):2524-2531. doi: 10.1080/10428194.2019.1594212. Epub 2019 Apr 3.

PMID:
30942640
7.

Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.

Peiró I, Palmero R, Iglesias P, Díez JJ, Simó-Servat A, Marín JA, Jiménez L, Domingo-Domenech E, Mancho-Fora N, Nadal E, Villabona C.

Endocrine. 2019 Jun;64(3):605-613. doi: 10.1007/s12020-019-01871-7. Epub 2019 Feb 25.

PMID:
30805887
8.

Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).

Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C.

Ann Oncol. 2019 Apr 1;30(4):612-620. doi: 10.1093/annonc/mdz009.

PMID:
30657848
9.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group.

Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Erratum in: Lancet. 2019 Jan 19;393(10168):228.

PMID:
30522922
10.

Brentuximab vedotin for lymphoma in paediatric patients.

Sureda A, Domingo-Domènech E.

Lancet Haematol. 2018 Oct;5(10):e433-e434. doi: 10.1016/S2352-3026(18)30160-1. No abstract available.

PMID:
30290898
11.

Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.

Narváez J, Juarez-López P, LLuch J, Narváez JA, Palmero R, García Del Muro X, Nolla JM, Domingo-Domenech E.

Autoimmun Rev. 2018 Oct;17(10):1040-1045. doi: 10.1016/j.autrev.2018.05.002. Epub 2018 Aug 10. Review.

PMID:
30103042
12.

Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C.

Blood. 2017 Oct 12;130(15):1772-1774. doi: 10.1182/blood-2017-07-795302. Epub 2017 Aug 11. No abstract available.

PMID:
28801448
13.

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.

Magnano L, Montoto S, González-Barca E, Briones J, Sancho JM, Muntañola A, Salar A, Besalduch J, Escoda L, Moreno C, Domingo-Domenech E, Estany C, Oriol A, Altés A, Pedro C, Gardella S, Asensio A, Vivancos P, Fernández de Sevilla A, Ribera JM, Colomer D, Campo E, López-Guillermo A.

Ann Hematol. 2017 Apr;96(4):639-646. doi: 10.1007/s00277-017-2920-2. Epub 2017 Jan 18.

PMID:
28101592
14.

Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50 years.

Martínez C, Jorge AS, Pereira A, Moreno M, Núñez J, Gayoso J, Gonzalez-Medina J, Revilla N, Sampol A, Domingo-Domenech E, de la Cruz F, Morales A, Rodriguez-Salazar MJ, Valiente S, Pérez-Ceballos E, de Oteyza JP, García-Sanz R; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO).

Ann Hematol. 2017 Jan;96(1):9-16. doi: 10.1007/s00277-016-2832-6. Epub 2016 Oct 18.

PMID:
27752822
15.

Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.

González-Barca E, Canales MA, Salar A, Ferrer S, Domingo-Domenech E, Vidal MJ, Grande C, Bargay J, Gardella S, Oriol A, Briones J, García-Frade J, Bello JL, Sánchez-Blanco JJ, Peñalver FJ, Tomás JF, Asensio A, López A, Caballero D; GELTAMO Group (Grupo Español de Linfoma y Trasplante de Médula Ósea).

Acta Haematol. 2016;136(2):76-84. doi: 10.1159/000444625. Epub 2016 May 18.

PMID:
27188649
16.

Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.

Martínez C, Díaz-López A, Rodriguez-Calvillo M, García-Sanz R, Terol MJ, Pérez-Ceballos E, Jiménez MJ, Cantalapiedra A, Domingo-Domenech E, Rodriguez MJ, Sampol A, Espeso M, López FJ, Briones J, García JF, Sureda A; Hodgkin Lymphoma Subcommittee of Spanish Group of Lymphoma Bone Marrow Transplantation(GELTAMO).

Br J Haematol. 2016 Sep;174(6):859-67. doi: 10.1111/bjh.14133. Epub 2016 May 17.

PMID:
27185197
17.

CCR5 Δ32 homozygous cord blood allogeneic transplantation in a patient with HIV: a case report.

Duarte RF, Salgado M, Sánchez-Ortega I, Arnan M, Canals C, Domingo-Domenech E, Fernández-de-Sevilla A, González-Barca E, Morón-López S, Nogues N, Patiño B, Puertas MC, Clotet B, Petz LD, Querol S, Martinez-Picado J.

Lancet HIV. 2015 Jun;2(6):e236-42. doi: 10.1016/S2352-3018(15)00083-1. Epub 2015 May 19.

PMID:
26423196
18.

The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment.

Sancho JM, García O, Mercadal S, Pomares H, Fernández-Alvarez R, González-Barca E, Tapia G, González-García E, Moreno M, Domingo-Domènech E, Sorigué M, Navarro JT, Motlló C, Fernández-de-Sevilla A, Feliu E, Ribera JM.

Leuk Res. 2015 Aug;39(8):853-8. doi: 10.1016/j.leukres.2015.05.009. Epub 2015 May 28.

PMID:
26122511
19.

Clinico-biological features, treatment and survival of 457 patients with histological Grades 3A and 1-2 follicular lymphoma mostly treated with immunochemotherapy.

Mercadal S, Pomares H, Sancho JM, Climent F, García O, Encuentra M, Domingo-Doménech E, Sorigué M, Moreno M, Oliveira AC, Ribera JM, Fernández de Sevilla A, González-Barca E.

Br J Haematol. 2016 Feb;172(3):470-3. doi: 10.1111/bjh.13502. Epub 2015 May 26. No abstract available.

PMID:
26010479
20.

Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection.

Marín M, Gudiol C, Ardanuy C, Garcia-Vidal C, Jimenez L, Domingo-Domenech E, Pérez FJ, Carratalà J.

Clin Microbiol Infect. 2015 Jun;21(6):583-90. doi: 10.1016/j.cmi.2015.01.029. Epub 2015 Feb 11.

21.

Prospective study of prognostic factors in asymptomatic patients with B-cell chronic lymphocytic leukemia-like lymphocytosis: the cut-off of 11 × 10(9)/L monoclonal lymphocytes better identifies subgroups with different outcomes.

Oliveira AC, Fernández de Sevilla A, Domingo A, De La Banda E, Domingo-Domènech E, Mercadal S, Ruiz-Xivillé N, Alonso E, Encuentra M, González-Barca E.

Ann Hematol. 2015 Apr;94(4):627-32. doi: 10.1007/s00277-014-2263-1. Epub 2014 Dec 5.

PMID:
25471173
22.

First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO).

Lancet Haematol. 2014 Dec;1(3):e104-11. doi: 10.1016/S2352-3026(14)00021-0. Epub 2014 Nov 19.

PMID:
27029228
23.

Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience.

García-Noblejas A, Martínez Chamorro C, Navarro Matilla B, Da Silva Rodriguez C, González-Lopez TJ, Oña Navarrete R, Ramírez Sánchez MJ, Martínez Barranco P, Sánchez Blanco JJ, Nicolás C, Pérez R, Sánchez González B, Ruedas López AM, Domingo-Domenech E, Panizo C, Macia S, Fernández-Fonseca E, Cannata-Ortiz J, Arranz R.

Ann Hematol. 2014 Sep;93(9):1551-8. doi: 10.1007/s00277-014-2077-1. Epub 2014 Apr 30.

PMID:
24782117
24.

Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients.

Bodro M, Gudiol C, Garcia-Vidal C, Tubau F, Contra A, Boix L, Domingo-Domenech E, Calvo M, Carratalà J.

Support Care Cancer. 2014 Mar;22(3):603-10. doi: 10.1007/s00520-013-2012-3. Epub 2013 Oct 30.

PMID:
24170166
25.

Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use.

Montalban C, Abraira V, Arcaini L, Domingo-Domenech E, Guisado-Vasco P, Iannitto E, Mollejo M, Matutes E, Ferreri AJ, Salar A, Rattotti S, Carpaneto A, Perez R, Bello JL, Hernandez M, Caballero D, Carbonell F, Piris MA; Splenic Marginal Zone Lymphoma Study Group (SMZLSG).

Leuk Lymphoma. 2014 Apr;55(4):929-31. doi: 10.3109/10428194.2013.818143. Epub 2013 Jul 29. No abstract available.

PMID:
23799931
26.

Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.

Servitje O, Muniesa C, Benavente Y, Monsálvez V, Garcia-Muret MP, Gallardo F, Domingo-Domenech E, Lucas A, Climent F, Rodriguez-Peralto JL, Ortiz-Romero PL, Sandoval J, Pujol RM, Estrach MT.

J Am Acad Dermatol. 2013 Sep;69(3):357-65. doi: 10.1016/j.jaad.2013.04.047. Epub 2013 Jun 21.

PMID:
23796549
27.

Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy.

Mercadal S, Climent F, Domingo-Doménech E, Oliveira A, Romagosa V, de Sevilla AF, González-Barca E.

Clin Med Insights Blood Disord. 2013 Nov 14;6:23-7. doi: 10.4137/CMBD.S12713. eCollection 2013.

28.

Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases.

Montalbán C, Abraira V, Arcaini L, Domingo-Domenech E, Guisado-Vasco P, Iannitto E, Mollejo M, Matutes E, Ferreri A, Salar A, Rattotti S, Carpaneto A, Pérez Fernández R, Bello JL, Hernández M, Caballero D, Carbonell F, Piris MA; Splenic Marginal Zone Lymphoma Study Group.

Br J Haematol. 2012 Oct;159(2):164-71. doi: 10.1111/bjh.12011. Epub 2012 Aug 24. Erratum in: Br J Haematol. 2013 Sep;162(6):864. Iannito, Emilio [corrected to Iannitto, Emilio].

PMID:
22924582
29.

Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients.

Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, Domingo-Domenech E, Jiménez L, Carratalà J.

Clin Microbiol Infect. 2013 May;19(5):474-9. doi: 10.1111/j.1469-0691.2012.03879.x. Epub 2012 Apr 24.

30.

Biological agents in the management of Felty's syndrome: a systematic review.

Narváez J, Domingo-Domenech E, Gómez-Vaquero C, López-Vives L, Estrada P, Aparicio M, Martín-Esteve I, Nolla JM.

Semin Arthritis Rheum. 2012 Apr;41(5):658-68. doi: 10.1016/j.semarthrit.2011.08.008. Epub 2011 Nov 25. Review.

PMID:
22119104
31.

NT-proBNP: a cardiac biomarker to assess prognosis in non-Hodgkin lymphoma.

Gimeno E, Gómez M, González JR, Comín J, Alvarez-Larrán A, Sánchez-González B, Molina L, Domingo-Domenech E, Garcia-Pallarols F, Pedro C, Abella E, Vilaplana C, de Sanjosé S, Besses C, Salar A.

Leuk Res. 2011 Jun;35(6):715-20. doi: 10.1016/j.leukres.2011.01.018. Epub 2011 Feb 17.

PMID:
21333352
32.

Prospective study of clinical and biological prognostic factors at diagnosis in patients with early stage B-cell chronic lymphocytic leukemia.

Oliveira AC, de la Banda E, Domingo-Domenech E, Encuentra M, Mercadal S, Domingo A, Alonso E, Espinet B, Grau J, De Sevilla AF, Gonzalez-Barca E.

Leuk Lymphoma. 2011 Mar;52(3):429-35. doi: 10.3109/10428194.2010.545463.

PMID:
21323523
33.

Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.

Salar A, Domingo-Domenech E, Estany C, Canales MA, Gallardo F, Servitje O, Fraile G, Montalbán C.

Cancer. 2009 Nov 15;115(22):5210-7. doi: 10.1002/cncr.24605.

34.

High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.

Montoto S, Moreno C, Domingo-Doménech E, Estany C, Oriol A, Altés A, Besalduch J, Pedro C, Gardella S, Escoda L, Asensio A, Vivancos P, Galán P, de Sevilla AF, Ribera JM, Briones J, Colomer D, Campo E, Montserrat E, López-Guillermo A; Grup per l'Estudi dels Limfomes de Catalunya I Balears (GELCAB) Spain.

Haematologica. 2008 Feb;93(2):207-14. doi: 10.3324/haematol.11671. Epub 2008 Jan 26.

35.

All-trans retinoic acid-induced myositis in a case of acute promyelocytic leukaemia.

Oliveira AC, Domingo-Domenech E, Arnan M, Gallardo D, Puig I, González-Barca E.

Int J Lab Hematol. 2008 Jun;30(3):254-5. doi: 10.1111/j.1751-553X.2007.00933.x. Epub 2008 Jan 18. No abstract available.

PMID:
18205843
36.

Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.

González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF; GEL/TAMO (Grupo Español de Linfomas); GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear); GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas).

Haematologica. 2007 Nov;92(11):1489-94.

37.

Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms.

Domingo-Domènech E, Benavente Y, González-Barca E, Montalban C, Gumà J, Bosch R, Wang SS, Lan Q, Whitby D, Fernández de Sevilla A, Rothman N, de Sanjosé S.

Haematologica. 2007 Nov;92(11):1475-81.

38.

Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study.

Salar A, Juanpere N, Bellosillo B, Domingo-Domenech E, Espinet B, Seoane A, Romagosa V, Gonzalez-Barca E, Panades A, Pedro C, Nieto M, Abella E, Solé F, Ariza A, Fernández-Sevilla A, Besses C, Serrano S.

Am J Surg Pathol. 2006 Oct;30(10):1274-80.

PMID:
17001159
39.

Influence of familial cancer history on lymphoid neoplasms risk validated in the large European case-control study epilymph.

Casey R, Brennan P, Becker N, Boffetta P, Cocco P, Domingo-Domenech E, Foretova L, Nieters A, de Sanjosé S, Staines A, Vornanen M, Maynadié M.

Eur J Cancer. 2006 Oct;42(15):2570-6. Epub 2006 Aug 22.

PMID:
16928444
40.

Acquired hypophosphatemic osteomalacia associated with multiple myeloma.

Narvaez J, Domingo-Domenech E, Narvaez JA, Nolla JM, Valverde J.

Joint Bone Spine. 2005 Oct;72(5):424-6. Epub 2005 Jan 26.

PMID:
16112595
41.

Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems.

Perea G, Altés A, Montoto S, López-Guillermo A, Domingo-Doménech E, Fernández-Sevilla A, Ribera JM, Grau J, Pedro C, Angel Hernández J, Estany C, Briones J, Martino R, Sureda A, Sierra J, Montserrat E.

Ann Oncol. 2005 Sep;16(9):1508-13. Epub 2005 Jun 6.

PMID:
15939718
42.

Regular use of hair dyes and risk of lymphoma in Spain.

Benavente Y, Garcia N, Domingo-Domenech E, Alvaro T, Font R, Zhang Y, de Sanjose S.

Int J Epidemiol. 2005 Oct;34(5):1118-22. Epub 2005 May 24.

PMID:
15914502
43.

Family clustering of blood cancers as a risk factor for lymphoid neoplasms.

Domingo-Domènech E, Benavente Y, Alvaro T, Hernández M, de Sevilla AF, de Sanjosé S.

Haematologica. 2005 Mar;90(3):416-8.

44.

Occupational exposure to immunologically active agents and risk for lymphoma.

Kogevinas M, Zock JP, Alvaro T, Garcia-Villanueva M, Domingo-Domenech E, Kennedy S, Martínez-Maza O, de Sanjose S.

Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1814-8.

45.

Radiological features of non-gastric mucosa-associated lymphoid tissue lymphomas.

Narváez JA, Domingo-Domènech E, Roca Y, Romagosa V, De Lama E, González-Barca E, Petit J, Fernández-Sevilla A.

Curr Probl Diagn Radiol. 2004 Sep-Oct;33(5):212-25. Review. No abstract available.

PMID:
15459631
46.

Role of hepatitis C virus infection in malignant lymphoma in Spain.

de Sanjose S, Nieters A, Goedert JJ, Domingo-Domenech E, Fernandez de Sevilla A, Bosch R, Herrera P, Domingo A, Petit J, Bosch X, Kallinowski B.

Int J Cancer. 2004 Aug 10;111(1):81-5.

47.

Helicobacter pylori and malignant lymphoma in Spain.

de Sanjose S, Dickie A, Alvaro T, Romagosa V, Garcia Villanueva M, Domingo-Domenech E, Fernandez de Sevilla A, El-Omar E.

Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):944-8.

48.

Celiac disease and lymphoma risk: a multicentric case--control study in Spain.

Farré C, Domingo-Domenech E, Font R, Marques T, Fernandez de Sevilla A, Alvaro T, Villanueva MG, Romagosa V, de Sanjose S.

Dig Dis Sci. 2004 Mar;49(3):408-12.

PMID:
15139489
49.

Refractory cold agglutinin-immunohaemolytic anaemia associated to marginal zone lymphoma responding to rituximab.

Petit J, Clavo M, de Sevilla AF, González-Barca E, Domingo-Doménech E, Grañena A.

Hematol J. 2003;4(6):450-1.

PMID:
14671620
50.

Lack of serological evidence for an association between simian virus 40 and lymphoma.

de Sanjose S, Shah KV, Domingo-Domenech E, Engels EA, Fernandez de Sevilla A, Alvaro T, Garcia-Villanueva M, Romagosa V, Gonzalez-Barca E, Viscidi RP.

Int J Cancer. 2003 Apr 20;104(4):522-4. Erratum in: Int J Cancer. 2003 May 19;104(6)800.

Supplemental Content

Loading ...
Support Center